MUC-1 recognition-based activated drug nanoplatform improves doxorubicin chemotherapy in breast cancer
Pilei Si1, Jinjin Shi2, Pei Zhang3
1Department of Breast Surgery, Henan Provincial People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Zhengzhou University People's Hospital, Zhengzhou, 450003, China; Department of Breast Surgery, Henan University People's Hospital, Zhengzhou, 450003, China.
Abstract:
Tumor-targeted drug delivery systems with stimuli-response drug release have been increasingly used to improve the therapeutic efficacy of antitumor drugs. Here, we report a specific molecular recognition activation drug nanoplatform based on specially designed DNA sensor-capped doxorubicin (DOX)-loaded mesoporous silica nanoparticles (MSNs), designated as specific molecular recognition-activated nanoparticle (SMRAN). DNA sensors on the targeted nanoparticles can trigger DOX release through a conformational switch induced by MUC-1. This causes a significant difference in cell viability between breast cancer MCF-7 and normal breast Hs578bst cells (24.8% and 86.0%). In vivo experiments showed that the tumor volume was reduced 1.5-times in the SMRAN treatment group. Compared with that in the DOX group, due to significantly improved tumor accumulation and retention of DOX. The strategy of the MUC-1 activated drug delivery system is expected to provide a new perspective for clinical application.
